Philippe Bey, PhD, is currently senior VP of R&D at Thrasos Therapeutics, a private Canadian, clinical-stage biotechnology company. Prior to joining Thrasos Therapeutics, from July 1999 to January 2003, he was CSO and senior VP of R&D of ArQule, a combinatorial chemistry biotechnology company. Previously Dr. Bey was at Hoechst Marion Roussel (HMR), now Sanofi, and its parent companies, from 1971 to 1999. He served in numerous science and management leadership positions both in Europe and the United States. His last position was U.S. senior VP of R&D and member of the HMR management team.
During his career, Dr. Bey has participated in and led teams responsible for more than 30 INDs in several therapeutic areas, including oncology. He also was responsible for bulk drug supply for preclinical and clinical studies. Philippe received his BS and PhD in chemistry from the University Louis Pasteur in Strasbourg, France. He was a post-doctoral trainee at the California Institute of Technology for two years and an adjunct professor of medicinal chemistry at the University Louis Pasteur in Strasbourg for twelve years. He has authored nearly 100 publications, 21 book chapters, and holds 63 issued patents. Dr. Bey is the inventor of difluoromethylornithine, (DFMO), the standard of care for African sleeping sickness.